Binding specificities and transducing function of the different molecular weight forms of insulin-like growth factor-II (IGF-II) on IGF-I receptors
- PMID: 1659523
- DOI: 10.1210/endo-129-6-3101
Binding specificities and transducing function of the different molecular weight forms of insulin-like growth factor-II (IGF-II) on IGF-I receptors
Abstract
In a study that was reported from this laboratory, the mitogenic potency of an apparent mol wt (appMr) of 15,000 precursor form of human insulin-like growth factor-II (hIGF-II) was shown to be greater than that of completely processed hIGF-II for human fetal-derived fibroblasts, and both were more potent than rIGF-I. Since it is generally acknowledged that the stimulation of cell replication by the IGFs is mediated by IGF-I receptors, we undertook to determine whether differences between the receptors' affinity for the two Mr forms of hIGF-II and recombinant IGF-I (rIGF-I) or between its efficiency to couple specific growth factor occupancy to the activation of protein kinase could explain the greater replicating potential of appMr 15,000 hIGF-II. Equilibrium dissociation, i.e. Kd, and inhibition, i.e. Ki, constants were determined by measuring the ability of rIGF-I, hIGF-II, appMr 15,000 hIGF-II, insulin, and the antireceptor monoclonal antibody alpha IR-3 to compete with 125I-labeled rIGF-I and hIGF-II for binding to purified preparations of IGF-I receptors prepared from an enriched source of fetal membrane, i.e. human term placenta. The results of these experiments established that 1) hIGF-II and appMr 15,000 hIGF-II bind to the IGF-I receptor with the same affinity as rIGF-I, e.g. with Kd and Ki values between 0.03-0.07 nM; 2) the total binding capacity, i.e. Ro, for IGF-I binding was not statistically different from the Ro calculated for IGF-II binding; and 3) the statistical analysis of 12 data sets from the competitive binding experiments for goodness of fit indicated that a 1-site model for IGF-I and -II binding was a better fit of the data than a 2-site model. Measurements of the stimulation of IGF-I receptor autophosphorylation at low ligand concentrations established that appMr 15,000 hIGF-II and hIGF-II were more effective than rIGF-I in coupling receptor occupancy to the activation of its protein kinase. At saturating ligand concentrations, the 3 had similar potencies. The original preparation of appMr 15,000 hIGF-II contains a mixture of forms with acidic isoelectric points (pIs) and was more potent than Mr 7,500 IGF-II in stimulating receptor autophosphorylation. These results are consistent with the relative potencies of this preparation, hIGF-II, and rIGF-I in stimulating the replication of 12-week-old fetal dermal fibroblasts.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor.J Biol Chem. 1991 Nov 5;266(31):20626-35. J Biol Chem. 1991. PMID: 1657932
-
Demonstration of type I and type II somatomedin receptors on bovine growth plate chondrocytes.J Orthop Res. 1988;6(6):817-26. doi: 10.1002/jor.1100060605. J Orthop Res. 1988. PMID: 2971791
-
Characterization of type I and type II insulin-like growth factor receptors in an intestinal epithelial cell line.Endocrinology. 1990 Jun;126(6):2998-3005. doi: 10.1210/endo-126-6-2998. Endocrinology. 1990. PMID: 2161743
-
Insulin-like growth factor receptors.J Cell Sci Suppl. 1985;3:39-51. doi: 10.1242/jcs.1985.supplement_3.5. J Cell Sci Suppl. 1985. PMID: 3011825 Review.
-
Somatomedin/insulin-like growth factor tissue receptors.Clin Endocrinol Metab. 1984 Mar;13(1):43-67. doi: 10.1016/s0300-595x(84)80008-0. Clin Endocrinol Metab. 1984. PMID: 6202447 Review.
Cited by
-
Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor.Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5356-60. doi: 10.1073/pnas.89.12.5356. Proc Natl Acad Sci U S A. 1992. PMID: 1319060 Free PMC article.
-
Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity.Growth Horm IGF Res. 2010 Apr;20(2):162-70. doi: 10.1016/j.ghir.2009.12.002. Epub 2010 Jan 25. Growth Horm IGF Res. 2010. PMID: 20089431 Free PMC article.
-
Insulin-like growth factor-II gene expression in a rat insulin-producing beta-cell line (INS-1) is regulated by glucose.Diabetologia. 1995 Aug;38(8):927-35. doi: 10.1007/BF00400581. Diabetologia. 1995. PMID: 7589878
-
Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells.Growth Factors. 2007 Dec;25(6):363-72. doi: 10.1080/08977190801886905. Growth Factors. 2007. PMID: 18365867 Free PMC article.
-
The Emerging Role of Glucose Metabolism in Cartilage Development.Curr Osteoporos Rep. 2019 Apr;17(2):59-69. doi: 10.1007/s11914-019-00506-0. Curr Osteoporos Rep. 2019. PMID: 30830516 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials